Evolution of Therapeutic Interventions in Ischemic Heart Disease: A Global Perspective

Ischemic heart disease (IHD) remains a leading cause of morbidity and mortality worldwide, significantly burdening healthcare systems. As populations age and lifestyles increasingly adopt unhealthy habits, the incidence of IHD continues to rise, prompting advancements in therapeutic interventions. According to the World Health Organization (WHO), IHD is a leading cause of death globally, accounting for millions of deaths each year. The continuous evolution of treatment modalities, from pharmacotherapy to surgical interventions, reflects the ongoing quest to enhance patient outcomes and manage the disease more effectively. Despite advancements, significant disparities exist in IHD treatment across different regions. Developed countries typically have access to advanced medical technologies and resources, offering higher standards of care. In contrast, developing nations often face challenges such as inadequate medical infrastructure and uneven healthcare quality, leading to suboptimal treatment outcomes for IHD patients. This paper aims to provide a comprehensive overview of the evolution of IHD therapeutic interventions from a global perspective, highlighting significant milestones and comparing treatment practices across various countries. By examining the application and effectiveness of different treatment methods, we seek to identify strengths and weaknesses in IHD management worldwide, offering insights for future improvements in global healthcare strategies.